



# SELECTIVE MODE

ANTIMICROBIAL RESISTANCE THERAPEUTICS

Fighting the post-antibiotic era with novel antimicrobial therapies

# THE POST-ANTIBIOTIC ERA IS HERE




“The convergence of antibiotic resistance and the collapse in the antibiotics R&D pipeline calls for urgent action. Nothing short of a global revival in antibiotics R&D is required”

- Dr. Margaret Chan

Director General of the World Health Organization

Anti-Microbial Resistance (AMR) is a major threat to human health in the future

# THE POST-ANTIBIOTIC ERA IS HERE



# THE SELMOD TEAM

## FOUNDERS

Philipp Knechtle Ph.D  
Pharma Executive



Prof. Roderich D. Süßmuth Dr.  
Prof. of Chemistry, TU Berlin



Markus Hofer MBA, MSc  
Biologist, Entrepreneur



Frank Otto Gombert Dr.  
Biochemist, Pharma Executive



## MANAGEMENT

Frank Otto Gombert Dr.  
CEO



Adam Belley Ph.D  
CSO




Bettina Hauptmann Eidens MBA,  
MSc  
COO



WORLD CLASS EXPERTISE IN ANTIBIOTIC DISCOVERY AND DEVELOPMENT

# SELMOD BUSINESS MODEL

Fighting the post-antibiotic era with novel antimicrobial therapies



# SELMOD ROBUST PIPELINE OF ANTIMICROBIAL AGENTS

PROJECT	BIOCHEMISTRY	THERAPY	IP STATUS	NEXT MILESTONES
slm 500	Novel chemical class Novel validated target	Serious bacterial infections*	Exclusive worldwide patent license acquired	Clinical development enabling, IND
slm 300	Novel chemical class Novel validated target	Serious bacterial infections*	In progress, expected by 2022	Lead optimization and in vivo pharmacology
slm 100	Novel chemical class Novel validated target	Systemic fungal infections	Patent filed 2021, pending	Lead optimization and in vivo pharmacology
*Includes complicated urinary tract infections, hospital acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, bacteremia				

# SELMOD IS OFFERING A 4 MILLION EURO INVESTMENT IN SERIES A FINANCING

Project	Year 1				Year 2				Milestones	Sum (Euro)
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4		
slm 500	[Bar spanning Year 1 Q1-Q4 and Year 2 Q1-Q2]								Clinical candidate ready for Phase 1	2 M
slm 300	[Bar spanning Year 1 Q1-Q3]								2 lead compounds validated	0.5 M
slm 100		[Bar spanning Year 1 Q2-Q4 and Year 2 Q1-Q2]							6 analogs ready for in-vivo studies	1.5 M

